HUM

Business profile & competitive position

Humana Inc. is a Louisville, Kentucky-based health company classified in the Healthcare / Medical – Healthcare Plans industry. It operates through two reportable segments: Insurance, which covers Medicare, state-based Medicaid, individual and employer plans, specialty benefits, military services and a pharmacy benefit manager; and CenterWell, which delivers pharmacy solutions, primary care and home-care services. As of December 31, 2025, Humana served approximately 15.0 million members in medical benefit plans and approximately 4.7 million members in specialty products. A striking 83% of its 2025 total premiums and services revenue came from contracts with the federal government, including 14% from individual Medicare Advantage contracts in Florida alone that cover roughly 1.0 million members.

The scale is real: CenterWell Primary Care operated 350 clinics, employed about 1,300 primary care providers and served approximately 491,100 patients as of year-end 2025. From a financial-moat perspective, however, the current numbers are modest. Return on equity is 6.9% and the net margin is 0.9%. Those profitability figures suggest the company’s competitive position is not translating into especially wide accounting returns right now. The integrated-care model, value-based provider arrangements and large membership base may create operating leverage over time, but the margin and ROE data alone do not support a claim of a deep, durable moat at this snapshot in time.

Financial posture

Humana’s current market capitalization is $47.2 billion, and its trailing P/E ratio stands at 36.9. That is a rich valuation against a net margin of 0.9% and an ROE of 6.9%. In effect, the market is pricing in a meaningful earnings recovery or margin normalization that has not yet shown up in the reported income statement. The stock’s beta of 0.74 indicates below-market volatility, consistent with a large, regulated insurer whose cash flows are tied to recurring premium revenue.

At the current price of $393.365, the Relative Strength Index is 51.9, essentially neutral, while the 50-day exponential moving average is $382.84. The stock is trading slightly above that moving average. The valuation disconnect is the central financial story here: a P/E near 37 implies healthy long-term earnings power, while the 0.9% net margin says current profitability is thin. Readers should weigh whether the market is looking through a temporary trough or whether the multiple simply reflects the defensive, government-backed revenue stream.

Strategic priorities & outlook

Humana’s most recent 10-K filing outlines four operational priorities. The first is to run an integrated care delivery model that combines quality care, high member engagement and sophisticated data analytics. The second is to improve the consumer experience by making interactions with Humana simpler. Third, the company wants to engage members more deeply in clinical programs. Fourth, it is pushing providers to shift from fee-for-service toward value-based arrangements.

Those priorities line up with the reported business mix. Approximately 2,260,900 members, or 15.1% of medical membership, were already covered under shared-risk value-based arrangements as of December 31, 2025, including 37.1% of total individual Medicare Advantage membership. The filing’s emphasis on value-based care, consumer experience and clinical engagement gives investors a concrete lens through which to judge quarterly execution, rather than relying on revenue growth alone.

Macro & geopolitical exposure

As a Medical – Healthcare Plans company, Humana carries the standard macro and geopolitical exposures of a U.S.-focused managed-care insurer. The dominant factor is U.S. federal healthcare policy, because Medicare and Medicaid reimbursement rates, Medicare Advantage funding levels, and regulatory changes from the Centers for Medicare & Medicaid Services flow directly into revenue and margins. With 83% of premiums and services revenue tied to federal contracts, rate announcements and political debates over entitlement spending matter far more to this stock than commodity or currency moves.

Other relevant industry-wide exposures include state Medicaid budget pressures, prescription-drug pricing legislation, antitrust scrutiny of vertical integration involving PBMs and care-delivery assets, and broader interest-rate movements that affect investment income on the float. Trade policy is not a core driver here; the business is overwhelmingly domestic. In short, the macro playbook for Humana is primarily a Washington playbook.

Recent developments

Recent headlines have been mixed. On September 25, 2026, 247wallst.com reported that Humana jumped 7% following a Barclays upgrade to Overweight and a $515 price target, while UnitedHealth nudged higher. That $515 target implies meaningful upside from the current $393.365 price level, although price targets are estimates, not guarantees. On September 18, 2026, defenseworld.net noted that Corient Private Wealth LP cut its stake in Humana, an incremental institutional outflow.

On the operational front, a September 17, 2026 Business Wire release highlighted new Humana research finding an association between pharmacy care coordination services and improved health outcomes for cancer patients. That fits the 10-K emphasis on clinical engagement and integrated care. The same day, defenseworld.net reported that Bank of America Corp DE invested $279.49 million in Humana, an offsetting institutional inflow. The news flow therefore captures both analyst bullishness and real institutional repositioning, against a backdrop of the company promoting its clinical-program outcomes.

Earnings behavior & post-earnings drift

Humana’s recent earnings history is unusual. Over the last eight reported quarters, the company has beaten consensus EPS estimates every time, for a 100% beat rate, with an average earnings surprise of 7.9%. Yet the average 5-day price move after those reports is just 0.06%, classified as flat. This is a clear example of a “beat ≠ pop and hold” dynamic.

The last four quarters illustrate the disconnect:

• On July 29, 2026, Humana reported $7.61 versus a $7.27 estimate, a 4.7% beat; the stock rose 0.34% the next day but fell 0.44% over the next five sessions.
• On April 29, 2026, EPS was $10.31 against $10.24, only a 0.7% beat; the stock dropped 2.75% the next day and recovered 1.32% over five days.
• On February 11, 2026, the company posted -$3.96 versus -$4.00, a 1% beat; shares rallied 1.96% the next day and 8.61% over the following five days.
• On November 5, 2025, EPS of $3.24 beat the $2.93 estimate by 10.6%, but the stock fell 5.22% the next day and 9.23% over the next five days.

What this pattern suggests is that the market’s real expectation may already be embedded in the price, or that headline beats are being met with questions about guidance, forward-year Medicare Advantage margins, or medical-cost trends. The next report is scheduled for November 6, 2026, before the open, with a consensus EPS estimate of -$1.04. Given the 100% beat streak, the question for traders is less about whether Humana can clear the consensus number and more about how the stock reacts once it does.

For a deeper dive into how sell-side and institutional models are currently positioned on Humana, including forward-looking consensus revisions and the full institutional verdict, explore the complete research dashboard rather than relying on price action alone.